Skip to main content

Table 2 Multivariate analysis of S100A8/A9, LDH, and M stage on progression-free survival in the pembrolizumab-treated patients (pembrolizumab set 2)

From: Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

 Patients 
No.%%
Prog.
HR95% CIp value
S100A8/A9
 ≤ 5.5 mg/l3988.648.71  
 > 5.5 mg/l511.4100.010.12.72–37.6.00055
LDH
 ≤ 2,5xULN4090.952.51  
 > 2,5xULN49.175.02.190.48–10.1.31
M stage
 M0/M1a/b1431.857.11  
 M1c3068.253.30.680.22–2.08.50
  1. NOTE. Multivariate survival analysis included 44 patients of the pembrolizumab set 2. The model was adjusted for age and sex
  2. Abbreviations: CI confidence interval, HR hazard ratio, ICI immune checkpoint inhibitor, LDH lactate dehydrogenase, Prog. progression, ULN upper limit of normal